PRIMARY IMMUNE THROMBOCYTOPENIA
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Last-resort drug access program opens for rare immune disorders
Disease control AVAILABLEThis program provides access to the experimental drug VAY736 (ianalumab) for patients with serious or life-threatening immune conditions like primary immune thrombocytopenia or Sjögren's syndrome. It is only available when no other treatments work and the patient cannot join a cl…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Second dose hope: retrial of drug for rare blood diseases
Disease control Recruiting nowThis study tests a second round of ianalumab in 60 adults with primary immune thrombocytopenia (ITP) or warm-antibody autoimmune hemolytic anemia (wAIHA) who previously responded to the drug. The goal is to see if retreatment can control the disease again after it returns. Partic…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New shot aims to boost platelets in chronic blood disorder
Disease control Recruiting nowThis study tests an experimental drug called PF-06835375 in adults with moderate to severe primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. The drug is given as multiple injections under the skin. The main goal…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 05, 2026 11:54 UTC
-
500 kids with rare bleeding disorder to be tracked in landmark study
Knowledge-focused Recruiting nowThis study follows 500 children aged 6-17 diagnosed with immune thrombocytopenia (ITP), a rare condition where the immune system destroys platelets, causing bruising and bleeding. Researchers will track their symptoms, treatments, and outcomes over time to build a clearer picture…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated May 26, 2026 04:08 UTC